SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-031467
Filing Date
2024-03-14
Accepted
2024-03-14 16:06:40
Documents
14
Period of Report
2024-03-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K lrmr-20240314.htm   iXBRL 8-K 40598
2 EX-99.1 lrmr-ex99_1.htm EX-99.1 135960
3 GRAPHIC img46574298_0.jpg GRAPHIC 282533
  Complete submission text file 0000950170-24-031467.txt   664205

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT lrmr-20240314.xsd EX-101.SCH 23892
15 EXTRACTED XBRL INSTANCE DOCUMENT lrmr-20240314_htm.xml XML 4533
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Filer) CIK: 0001374690 (see all company filings)

IRS No.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36510 | Film No.: 24749757
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)